Skip to main content
. 2019 Aug 7;146(7):1917–1929. doi: 10.1002/ijc.32583

Figure 3.

Figure 3

The comparison of overall survival (OS) between patients that did not receive a pertuzumab‐based regimen in first‐line and did not receive T‐DM1 as a second‐line of treatment (No/No, red color), patients that did not receive a pertuzumab‐based regimen in first‐line and received T‐DM1 as a second‐line of treatment (No/Yes, green color), patients that received a pertuzumab‐based regimen in first‐line and T‐DM1 as a second‐line of treatment (Yes/Yes, gray color) and those who received a pertuzumab‐based regimen in first‐line and did not receive T‐DM1 as a second‐line of treatment (Yes/No, blue color). The comparison was done in the overall population (a), in triple‐positive patients (b), in Er o PgR positive patients (c) and in HRs negative patients (d). The adjacent percentages to each survival curve refer to the 3‐year survival rate.